Start here if you're new
what it is
Nuvectis develops cancer drugs for serious oncology diseases with few good treatments.
how it gets paid
Last year Nuvectis had no product revenue (n/a). Program rows at $0 are placeholders—do not read a “40% mix” with zero sales.
what just happened
Nuvectis posted a $0.36 fourth-quarter loss per share in 2024.
At a glance
B balance sheet — gets the job done, barely
-$1.11 fy2024 eps est
deep operating loss — pre-revenue (ignore bogus margin %)
1.05 beta
~$239M market cap
xvary composite: 47/100 — below average
What they do
Nuvectis develops cancer drugs for serious oncology diseases with few good treatments.
It has exclusive worldwide rights to NXP800 and NXP900. Exclusive rights mean only one company gets the upside if the drugs work. That matters more when you have 13 employees and two clinical-stage programs, not a broad portfolio.
How they make money
n/a
annual revenue
NXP800 program
$0
NXP900 program
$0
R&D support
$0
Corporate and admin
$0
The products that matter
precision oncology drug candidate
NXP900
$0 revenue today · $26.4M net loss in 2025
It is the entire equity story right now. The company generated $0 revenue and lost $26.4M in 2025, so every dollar of market value rests on NXP900 producing credible clinical evidence.
the whole thesis
Key numbers
$239M
market cap
Market cap means what the whole company is worth. $239M is small enough that one trial headline can move it hard.
13
headcount
Thirteen employees means a tiny team has to carry 2 drug programs. That is a lot of pressure for one lunch table.
-$1.11
fy2024 eps
EPS means earnings per share after costs. -$1.11 says the company lost about $1.11 per share in 2024.
1.05
beta
Beta means how wild the stock swings versus the market. 1.05 means it moves about like the market, not like a sleepy utility.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for NVCT right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Nuvectis posted a -$0.36 fourth-quarter EPS loss in 2024.
The company is still pre-revenue. Annual EPS improved from -$1.43 in 2023 to -$1.11 in 2024, which is better, but still a loss.
$0
revenue
-$0.36
eps
n/a
n/a
loss per share
The quarter lost $0.36 per share. That matters because there is no sales cushion yet.
source: quarterly EPS history, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is NXP900 failing to generate meaningful clinical progress before dilution becomes the story.
med
Single-asset clinical failure
You do not have diversification here. The company has $0 revenue, no approved products, and one lead candidate carrying the current $239M equity value.
If NXP900 disappoints, the investment case does not weaken around the edges. It largely disappears.
med
Regulatory and development delay
Even good early data is not approval. NXP900 still has to keep advancing through the clinical and regulatory process, and the company has not reached pivotal-stage proof.
Delays stretch the timeline, increase financing pressure, and push any real revenue further into the future.
med
Dilution is not theoretical
The February 2026 shelf plus at-the-market program totals $210M. That is nearly as large as the current $239M market cap.
If management uses that capacity heavily, your percentage ownership can shrink long before the science pays you back.
med
Rising burn rate
Annual net loss increased from $19.0M to $26.4M. That is normal for a company pushing a program forward, but it still means the clock does not stop.
A rising burn with no matching clinical de-risking makes each future financing round more painful.
With $0 revenue, a $26.4M annual loss, and up to $210M of financing capacity filed in February 2026, the downside can hit both the science and your share count.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next earnings and filing update
The next report is the easiest scheduled moment to see whether the $26.4M annual loss is still climbing or beginning to level out.
clinical progress
NXP900 development milestones
This is the real catalyst path. Without visible clinical advancement, the $239M valuation has less to lean on.
financing
use of the $150M shelf and $60M ATM
The filings are in place. What matters next is whether management actually taps them, and on what terms.
burn rate
loss trend from $19.0M to $26.4M
You want the spending step-up to buy real development progress. If expenses rise and the science stays quiet, the story gets worse.
Analyst rankings
risk profile
average
risk rank 3 — typical risk profile — neither especially safe nor risky.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for NVCT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$8
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive